Literature DB >> 7559879

Morbidity and mortality in follicular thyroid cancer.

L J DeGroot1, E L Kaplan, M S Shukla, G Salti, F H Straus.   

Abstract

The natural history and results of treatment have been analyzed in a group of 49 patients with follicular thyroid carcinoma who were followed for an average of 10.7 yr. Striking differences between the course of follicular thyroid carcinoma and the course of papillary carcinoma are evident. Deaths from cancer were double (16% for follicular), age at diagnosis was older, and age at death was younger. All deaths and recurrences happened within 13 yr, in contrast to the continued experience of deaths and recurrences in papillary cancer, even through 40 yr of observation. Adverse outcome correlated with extent of disease at diagnosis and with size of primary tumor, but did not correlate with vessel invasion, extent of capsule invasion, degree of dedifferentiation, extent of primary surgery, or radioactive iodide ablation. These observations are again in striking contrast to experience with papillary cancer. No patient with intrathyroidal disease who was under age 45 at diagnosis and with a primary tumor of less than 2.5 cm died. Our observations suggest that follicular cancer, even if apparently intrathyroidal, carries a high mortality rate in patients over age 45 or in those with tumors larger than 2.5 cm at the time of diagnosis and suggest that we must consider additional therapeutic measures in this group of patients, including larger radioiodine doses for initial therapy, external radiotherapy, and even possibly prophylactic chemotherapy.

Entities:  

Mesh:

Year:  1995        PMID: 7559879     DOI: 10.1210/jcem.80.10.7559879

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

Review 1.  Thyroid and aging.

Authors:  Mouhammed Habra; Nicholas J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

Review 2.  The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

3.  The importance of staging systems for the determination of prognosis of well-differentiated thyroid cancer.

Authors:  Varlık Erol; Özer Makay; Gökhan İçöz; Timur Köse; Yeşim Ertan; Ülkem Yararbaş; Mahir Akyıldız; Mustafa Yılmaz
Journal:  Ulus Cerrahi Derg       Date:  2013-03-01

4.  Mitochondrial DNA mutations in differentiated thyroid cancer with respect to the age factor.

Authors:  Jürgen Witte; Steffen Lehmann; Michael Wulfert; Quin Yang; Hans D Röher
Journal:  World J Surg       Date:  2007-01       Impact factor: 3.352

Review 5.  Differentiated thyroid cancer-personalized therapies to prevent overtreatment.

Authors:  Markus Luster; Theresia Weber; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2014-07-01       Impact factor: 43.330

6.  Follicular adenoma and carcinoma of the thyroid gland.

Authors:  Christopher R McHenry; Roy Phitayakorn
Journal:  Oncologist       Date:  2011-04-11

7.  Minimally invasive follicular thyroid carcinoma.

Authors:  C S Heffess; L D Thompson
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 8.  Radioiodine for remnant ablation and therapy of metastatic disease.

Authors:  Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

9.  Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival.

Authors:  Chung-Yau Lo; Wai-Fan Chan; King-Yin Lam; Koon-Yat Wan
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

10.  Risk factors for lateral cervical lymph node involvement in follicular thyroid carcinoma.

Authors:  Haitham Alfalah; Isaac Cranshaw; Thomas Jany; Laurent Arnalsteen; Emmanuelle Leteurtre; Catherine Cardot; François Pattou; Bruno Carnaille
Journal:  World J Surg       Date:  2008-12       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.